MaxCyte preliminary Q3 revenue $7.8-8.0M; cuts FY2023 revenue guidance to $34-36M

MAXCYTE, INC.

2023-Q3 EPS reported -$0.32 revenue$25,623,400

Q3 total revenue expected $7.8-8.0M, down 25-27% YoY; core revenue $6.4-6.6M, down 33-35% YoY.
FY2023 total revenue guidance reduced to ~$34-36M; core revenue guidance lowered to $28-30M.
SPL program-related revenue Q3 $1.4M vs $0.8M YoY; full-year SPL guidance unchanged at ~$6M.
Company cites depressed cell and gene therapy funding, customer inventory, and elongation of preclinical activity.
Ending cash expected ~$200M, unchanged from initial 2023 outlook.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. reported the quarter ended September 30, 2023 results: revenue $7.8 – 8.0 million. Guidance reaffirmed.

Period: the quarter ended September 30, 2023
Revenue: $7.8 – 8.0 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

preliminary revenue for the third quarter ended September 30, 2023 and updated its full year 2023 revenue guidance. Preliminary Third Quarter 2023 Revenue · Total revenue of $7.8 – 8.0 million in the third quarter of 2023, a decrease of 25 -27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector. ·

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-016235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.